Advanced Therapies for Human Immunodeficiency Virus
Human Immunodeficiency Virus (HIV) remains a significant global health challenge with approximately 38 million people currently having the virus worldwide. Despite advances in treatment development, the virus persists in the human population and still leads to new infections. The virus has a powerfu...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-07-01
|
| Series: | Medical Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3271/12/3/33 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850260307527598080 |
|---|---|
| author | Daniel Josef Lindegger |
| author_facet | Daniel Josef Lindegger |
| author_sort | Daniel Josef Lindegger |
| collection | DOAJ |
| description | Human Immunodeficiency Virus (HIV) remains a significant global health challenge with approximately 38 million people currently having the virus worldwide. Despite advances in treatment development, the virus persists in the human population and still leads to new infections. The virus has a powerful ability to mutate and hide from the human immune system in reservoirs of the body. Current standard treatment with antiretroviral therapy effectively controls viral replication but requires lifelong adherence and does not eradicate the virus. This review explores the potential of Advanced Therapy Medicinal Products as novel therapeutic approaches to HIV, including cell therapy, immunisation strategies and gene therapy. Cell therapy, particularly chimeric antigen receptor T cell therapy, shows promise in preclinical studies for targeting and eliminating HIV-infected cells. Immunisation therapies, such as broadly neutralising antibodies are being investigated to control viral replication and reduce reservoirs. Despite setbacks in recent trials, vaccines remain a promising avenue for HIV therapy development. Gene therapy using technologies like CRISPR/Cas9 aims to modify cells to resist HIV infection or eliminate infected cells. Challenges such as off-target effects, delivery efficiency and ethical considerations persist in gene therapy for HIV. Future directions require further research to assess the safety and efficacy of emerging therapies in clinical trials. Combined approaches may be necessary to achieve complete elimination of the HIV reservoir. Overall, advanced therapies offer new hope for advancing HIV treatment and moving closer to a cure. |
| format | Article |
| id | doaj-art-6b74fc5a4ea84799b042ade72f92a17f |
| institution | OA Journals |
| issn | 2076-3271 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medical Sciences |
| spelling | doaj-art-6b74fc5a4ea84799b042ade72f92a17f2025-08-20T01:55:40ZengMDPI AGMedical Sciences2076-32712024-07-011233310.3390/medsci12030033Advanced Therapies for Human Immunodeficiency VirusDaniel Josef Lindegger0Independent Researcher, 6000 Lucerne, SwitzerlandHuman Immunodeficiency Virus (HIV) remains a significant global health challenge with approximately 38 million people currently having the virus worldwide. Despite advances in treatment development, the virus persists in the human population and still leads to new infections. The virus has a powerful ability to mutate and hide from the human immune system in reservoirs of the body. Current standard treatment with antiretroviral therapy effectively controls viral replication but requires lifelong adherence and does not eradicate the virus. This review explores the potential of Advanced Therapy Medicinal Products as novel therapeutic approaches to HIV, including cell therapy, immunisation strategies and gene therapy. Cell therapy, particularly chimeric antigen receptor T cell therapy, shows promise in preclinical studies for targeting and eliminating HIV-infected cells. Immunisation therapies, such as broadly neutralising antibodies are being investigated to control viral replication and reduce reservoirs. Despite setbacks in recent trials, vaccines remain a promising avenue for HIV therapy development. Gene therapy using technologies like CRISPR/Cas9 aims to modify cells to resist HIV infection or eliminate infected cells. Challenges such as off-target effects, delivery efficiency and ethical considerations persist in gene therapy for HIV. Future directions require further research to assess the safety and efficacy of emerging therapies in clinical trials. Combined approaches may be necessary to achieve complete elimination of the HIV reservoir. Overall, advanced therapies offer new hope for advancing HIV treatment and moving closer to a cure.https://www.mdpi.com/2076-3271/12/3/33advanced therapy medicinal products (ATMP)cell therapygene therapyhuman immunodeficiency virus (HIV)trialsvaccines |
| spellingShingle | Daniel Josef Lindegger Advanced Therapies for Human Immunodeficiency Virus Medical Sciences advanced therapy medicinal products (ATMP) cell therapy gene therapy human immunodeficiency virus (HIV) trials vaccines |
| title | Advanced Therapies for Human Immunodeficiency Virus |
| title_full | Advanced Therapies for Human Immunodeficiency Virus |
| title_fullStr | Advanced Therapies for Human Immunodeficiency Virus |
| title_full_unstemmed | Advanced Therapies for Human Immunodeficiency Virus |
| title_short | Advanced Therapies for Human Immunodeficiency Virus |
| title_sort | advanced therapies for human immunodeficiency virus |
| topic | advanced therapy medicinal products (ATMP) cell therapy gene therapy human immunodeficiency virus (HIV) trials vaccines |
| url | https://www.mdpi.com/2076-3271/12/3/33 |
| work_keys_str_mv | AT danieljoseflindegger advancedtherapiesforhumanimmunodeficiencyvirus |